89bio Inc (ETNB)
8.86
-0.52
(-5.54%)
USD |
NASDAQ |
May 08, 13:07
89bio Enterprise Value: 339.13M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 07, 2024 | 339.13M |
May 06, 2024 | 359.13M |
May 03, 2024 | 323.90M |
May 02, 2024 | 289.62M |
May 01, 2024 | 279.14M |
April 30, 2024 | 256.29M |
April 29, 2024 | 258.19M |
April 26, 2024 | 232.48M |
April 25, 2024 | 231.53M |
April 24, 2024 | 262.95M |
April 23, 2024 | 295.33M |
April 22, 2024 | 332.47M |
April 19, 2024 | 310.57M |
April 18, 2024 | 291.52M |
April 17, 2024 | 318.18M |
April 16, 2024 | 338.18M |
April 15, 2024 | 349.61M |
April 12, 2024 | 381.03M |
April 11, 2024 | 411.50M |
April 10, 2024 | 449.59M |
April 09, 2024 | 483.87M |
April 08, 2024 | 473.40M |
April 05, 2024 | 470.54M |
April 04, 2024 | 460.07M |
April 03, 2024 | 481.02M |
Date | Value |
---|---|
April 02, 2024 | 453.40M |
April 01, 2024 | 467.69M |
March 28, 2024 | 534.28M |
March 27, 2024 | 503.42M |
March 26, 2024 | 493.14M |
March 25, 2024 | 506.23M |
March 22, 2024 | 521.19M |
March 21, 2024 | 516.51M |
March 20, 2024 | 504.36M |
March 19, 2024 | 560.46M |
March 18, 2024 | 624.04M |
March 15, 2024 | 710.06M |
March 14, 2024 | 624.98M |
March 13, 2024 | 690.43M |
March 12, 2024 | 649.29M |
March 11, 2024 | 651.16M |
March 08, 2024 | 654.90M |
March 07, 2024 | 663.31M |
March 06, 2024 | 580.09M |
March 05, 2024 | 542.69M |
March 04, 2024 | 733.44M |
March 01, 2024 | 625.91M |
February 29, 2024 | 518.38M |
February 28, 2024 | 545.50M |
February 27, 2024 | 543.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-64.08M
Minimum
May 09 2022
1.149B
Maximum
Jun 13 2023
317.63M
Average
269.67M
Median
Oct 27 2020
Enterprise Value Benchmarks
Madrigal Pharmaceuticals Inc | 3.817B |
Akero Therapeutics Inc | 993.87M |
Viking Therapeutics Inc | 7.813B |
Galectin Therapeutics Inc | 255.68M |
Terns Pharmaceuticals Inc | 108.63M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -40.24M |
Total Expenses (Quarterly) | 41.21M |
EPS Diluted (Quarterly) | -0.50 |
Earnings Yield | -22.69% |